News
05.26.09
Inson and
Aurolab sign letter of intent to partner in the development of Inson’s unique intraocular drug delivery devices in India. The devices are being developed to treat and prevent post-surgical infections and inflammation which occur after cataract surgery. Future human clinical trials are currently being planned at the
Aravind Eye Care System, which is today the largest and most productive eye care facility in the world.
05.20.09
Inson submits SBIR (Small Business Innovative Research) grant to the NIH for the development of translational technologies for the improvement of cataract care.
04.14.09
Inson hires Tom East (formerly Senior Director of Quality Affairs at Nastech Pharmaceutical) as new VP of Operations.
2.25.09
Inson Medical Systems has been chosen as one of three finalists for 'Best Life Science Investment' at the ZINO Life Sciences Investment Forum. The winner and associated $50k investment fund will be announced in late March. For more information >>
2.16.09
Inson Medical Systems has been selected to compete for a $50,000
investment fund at the ZINO Life Sciences Investment Forum, to
be held February 24, 2009, 2:00-6:00pm at the Pan Pacific Hotel
in Seattle. For more information >>
1.12.09
Inson has been invited by the Japanese External Trade Organization (JETRO) as one of only three US companies to attend partnering events in Osaka and Kobe, Japan.
12.30.08
Inson is selected to present at the WBBA's upcoming 2009 Invest Northwest Forum on March 17-18, 2009 in Seattle, WA.
For more information >>
12.11.08
Buddy Ratner, PhD, and Tueng Shen, MD, PhD, recently presented the current results of collaboration between Bellevue-based Inson Medical Systems and the University of Washington to develop a novel drug delivery device that can be attached to the haptic arms of an IOL.
Read article >>
12.09.08
Inson submits INAD (Investigational New Animal Drug) application to the Center for Veterinary Medicine to further study its IOL antibiotic delivery device.
12.05.08
Inson submits SBIR (Small Business Innovative Research) grant to the NIH to study the prevention of secondary cataracts with its unique delivery device.
11.17.08
Tracy Klein, MBA, joins Inson as CEO bringing 22 years of
pharmaceutical and biotech industry experience and leadership to the team.
09.16.08
Inson is ranked as one of the top 3 technology investment companies at the 3rd annual Zino Zillionaire Investment Forum (ZIFF).
08.15.08
Dr. Tueng Shen is interviewed in Ophthalmology Times on the benefits of a technology for cataract treatment licensed to Inson. Read article >>
08.12.08
Inson is featured in a Puget Sound Business Journal Press Release. Read article >>
08.11.08
Inson is selected to present at the 3rd annual Zino Zillionaire Investment Forum (ZIFF) on September 16th, 2008 in Seattle, WA
06.20.08
Dr. Jeanette Stein, an expert in self-assembled surfaces and biomaterials is promoted to the position of chief science officer
06.05.08
Inson is chosen as one of five companies to be invited to present at the Tacoma Angel Network's full membership luncheon on Wed, June 11th
05.21.08
Inson reaches an agreement-in-principle with veterinary scientists at Ohio State University's Veterinary School for in vivo tests on a new product.
05.20.08
Dr. Tueng Shen, MD, Ph.D. an ophthalmic surgeon responsible for the invention of one of Inson's primary technologies joins Inson’s Scientific Advisory Board
04.06.08
Inson hires Dr. Jeanette Stein as Senior Scientist
08.20.07
Inson is formed as the third Ratner Biomedical Group, LLC incubator company.
Spring, 2006
Ratner Biomedical Group, LLC is formed as an incubator for Seattle-based biomedical technology companies.